Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue: +466.4%
EPS: −40.3%
Free cash flow: −186.6%
Total debt: −66.6%

Quarter to September 2026, against a year earlier

Insider buying

132.01 3.89 +3.04%

Follow KYMR

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 4/9
Altman Z: 23.22
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Valuation Filings

Kymera Therapeutics, Inc. (KYMR) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, Kymera Therapeutics, Inc. (KYMR) trades at a P/B ratio of 8.2×. Over the past ten years it has ranged from 0.0× (September 2020) to 11.6× (September 2021); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KYMR/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Kymera Therapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KYMR/metrics/pb-ratio">Kymera Therapeutics, Inc. (KYMR) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	4.2×	15.19%
FY2024	3.6×	(3.55%)
FY2023	3.7×	37.06%
FY2022	2.7×	(58.77%)
FY2021	6.6×	74.94%
FY2020	3.8×	—
FY2019	0.0×	—

Period	P/B ratio	Change
Jun 2026	7.5×	41.37%
Mar 2026	5.3×	26.78%
Dec 2025	4.2×	(20.30%)
Sep 2025	5.2×	44.49%
23 more quarters	Free account

Against its own ten years

Low 0.0× High 11.6×

Ten-year median 3.9×

Current reading's percentile 94

Company	P/B ratio
IBRX ImmunityBio, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	1.7×
PCVX Vaxcyte, Inc. compare	3.3×
TECH Bio-Techne Corp compare	5.4×
KYMR Kymera Therapeutics, Inc.	7.8×
CAI Caris Life Sciences,�Inc. compare	12.7×
TGTX TG Therapeutics, Inc. compare	13.6×
TWST Twist Bioscience Corporation compare	17.1×
SMMT Summit Therapeutics PLC compare	17.8×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Kymera Therapeutics, Inc. (KYMR) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on KYMR

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on KYMR

Stockrow Weekly